Community Pride Care Center | |
901 South 4th Street, Battle Creek, Nebraska 68715 | |
(402) 675-7845 | |
Name | Community Pride Care Center |
---|---|
Location | 901 South 4th Street, Battle Creek, Nebraska |
Certified By | Medicare and Medicaid |
No. of Certified Beds | 50 |
Occupancy Rate | 69.8% |
Medicare ID (CCN) | 285208 |
Legal Business Name | City Of Battle Creek |
Ownership Type | Government - City |
Ratings from Surveys (Inspections): | |
Ratings from Quality Measures: | |
Ratings from Staffing Data: | |
Overall Rating: |
---|
News Archive
The Council for Responsible Nutrition (CRN), the dietary supplement industry's leading trade association, today called the National Academy of Sciences Institute of Medicine's (IOM) newly released report on the Dietary Reference Intake (DRI) levels for vitamin D "a modest step in the right direction that fell short of truly capturing the extensive and positive research that has consistently supported the need for people to significantly raise their vitamin D levels."
Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that the Arthritis Advisory Committee appointed by the U.S. Food and Drug Administration (FDA) recommended by a unanimous vote of 12 to 0 that XIAFLEX™ (collagenase clostridium histolyticum), a novel, first-in-class, orphan-designated, biologic, be granted marketing approval by the FDA for the treatment of Dupuytren's contracture.
An older medication originally approved to treat heart problems eases the symptoms of a very rare muscle disease that often leaves its sufferers stiff and in a good deal of pain, physicians and researchers report in the Oct. 3 issue of the Journal of the American Medical Association.
Mitochondria play an important role in neuronal apoptosis caused by cerebral ischemia. Researchers at the Affiliated Hospital of Qingdao University, China discovered transient ischemia led to cell apoptosis in the hippocampus and changes in memory and cognition of aged rats.
PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has received a Phase 2 grant in the amount of $986,000 from the National Institute of Health (NIH) to support the development of defensin mimetic antimicrobial compounds for the treatment of oral candidiasis. This grant will fund this research project through August 31, 2012. This award represents the 14th grant or research contract received to date by PolyMedix.
› Verified 1 days ago
Number of Facility Reported Incidents | 0 |
Number of Substantiated Complaints | 0 |
Number of Fines | 2 |
Total Amount of Fines in Dollars | $24505 |
Number of Payment Denials | 1 |
Total Number of Penalties | 3 |
Experience Measure | Provider | National Avg. |
---|---|---|
Percentage of long-stay residents whose need for help with daily activities has increased | 7.03 | 14.46 |
Percentage of long-stay residents who lose too much weight | 4.76 | 5.51 |
Percentage of low risk long-stay residents who lose control of their bowels or bladder | 46.59 | 48.41 |
Percentage of long-stay residents with a catheter inserted and left in their bladder | 2.27 | 1.79 |
Percentage of long-stay residents with a urinary tract infection | 5.16 | 2.65 |
Percentage of long-stay residents who have depressive symptoms | 9.21 | 5.05 |
Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
Percentage of long-stay residents experiencing one or more falls with major injury | 3.8 | 3.36 |
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 96.84 | 93.87 |
Percentage of long-stay residents who received an antipsychotic medication | 1.41 | 14.2 |
Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 72.41 | 83.88 |
Percentage of short-stay residents who newly received an antipsychotic medication | 0 | 1.79 |
Percentage of long-stay residents whose ability to move independently worsened | 13.91 | 17.09 |
Percentage of long-stay residents who received an antianxiety or hypnotic medication | 7.03 | 19.7 |
Percentage of high risk long-stay residents with pressure ulcers | 6.52 | 7.32 |
Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 91.91 | 95.98 |
Percentage of short-stay residents who made improvements in function | 0 | 67.99 |
Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 82.93 | 82.93 |
News Archive
The Council for Responsible Nutrition (CRN), the dietary supplement industry's leading trade association, today called the National Academy of Sciences Institute of Medicine's (IOM) newly released report on the Dietary Reference Intake (DRI) levels for vitamin D "a modest step in the right direction that fell short of truly capturing the extensive and positive research that has consistently supported the need for people to significantly raise their vitamin D levels."
Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that the Arthritis Advisory Committee appointed by the U.S. Food and Drug Administration (FDA) recommended by a unanimous vote of 12 to 0 that XIAFLEX™ (collagenase clostridium histolyticum), a novel, first-in-class, orphan-designated, biologic, be granted marketing approval by the FDA for the treatment of Dupuytren's contracture.
An older medication originally approved to treat heart problems eases the symptoms of a very rare muscle disease that often leaves its sufferers stiff and in a good deal of pain, physicians and researchers report in the Oct. 3 issue of the Journal of the American Medical Association.
Mitochondria play an important role in neuronal apoptosis caused by cerebral ischemia. Researchers at the Affiliated Hospital of Qingdao University, China discovered transient ischemia led to cell apoptosis in the hippocampus and changes in memory and cognition of aged rats.
PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has received a Phase 2 grant in the amount of $986,000 from the National Institute of Health (NIH) to support the development of defensin mimetic antimicrobial compounds for the treatment of oral candidiasis. This grant will fund this research project through August 31, 2012. This award represents the 14th grant or research contract received to date by PolyMedix.
› Verified 1 days ago
Community Pride Care Center Location: 901 South 4th Street, Battle Creek, Nebraska 68715 Phone: (402) 675-7845 |